Pharma Two B announces poster presentation on P2B001
Pharma Two B announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in ...
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly ...
Business Wire13d
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy R…
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry ...
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support ...
Eagle-Tribune16d
Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024
The abstract, selected for a poster presentation, is a Trials-in-Progress presentation of a Phase 1 investigator-initiated study of danvatirsen monotherapy followed by danvatirsen combination with ...
Morningstar14d
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination ...